Table 1

Baseline characteristics of the 79 patients included in the trial

Sulphasalazine (n=37) mean/n (%) Placebo (n=42) mean/n (%) Range
Age (years)33.135.219–57
Disease duration (total, months)4.73.91–315
Duration of present attack (months)2.52.81–65
Experiencing 1st attack26  (70)30  (71)
EXAM1-150 14  (38)15  (36)
HLA-B27 positive20  (54)27  (64)
Pathological xrays
Iliosacral joints4  (11)5  (12)
Peripheral joints9  (24)6  (14)
Positive serology/culture 12  (32)14  (33)
 Yersinia4 3 (1 also chlamydia)
 Borrelia10
 Salmonella11
 Chlamydia611
 Gonococci0 1  (also chlamydia)
ESR30321–120
Pain (mm VAS)46460–95
No of swollen joints3.23.51–10
No of patients on sick leave** 23  (62)31  (74)
  • 1-150 EXAM = presence of extra-articular manifestations (conjunctivitis, uveitis, urethritis, balanitis, skin/mucous membrane manifestations, entesopathy) **Within past 4 weeks, due to reactive arthritis. VAS, visual analogue scale.